
|Videos|April 10, 2020
Weekly Webinar Series Part 4: Managing Lung Cancer Patients Through the COVID-19 Pandemic
Advertisement
Episodes in this series

Led by Nathan Pennell, MD, PhD; Stephen Liu, MD; Charu Aggarwal, MD, MPH; H. Jack West, MD; and Jarushka Naidoo, MBBch, MHS, these top leaders in the lung cancer space shared insights on the novel corona-virus disease 2019 (COVID-19) and how the pandemic is poised to have a significant impact on lung cancer treatment and the healthcare system.
This webinar covered key information regarding:
- Insight from Jarushka Naidoo, MBBCh, and the general steps being taken by Johns Hopkins Medicine regarding COVID-19
- Immunotherapy adaptions in the era of COVID-19, with a special focus on pneumonitis
- Cased-based discussions surrounding imaging
Advertisement
Related to this article

Trastuzumab deruxtecan plus pertuzumab improved systemic and intracranial outcomes in HER2-positive breast cancer with baseline brain metastases.

Petosemtamab plus pembrolizumab cut the risk of death by 50% in first-line PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma.

Relacorilant plus nab-paclitaxel and bevacizumab produced a 59% response rate in platinum-resistant ovarian cancer in Part A of the BELLA trial.

Updated ASTRO recommendations favor moderate hypofractionation for all risk groups and establish 5-fraction ultrahypofractionation as a standard option in localized prostate cancer.

Updated GOBLET cohort 4 data showed a median DOR of about 15 months with pelareorep plus atezolizumab in second-line or later anal cancer.

Firmonertinib demonstrated durable antitumor activity in patients with EGFR PACC-mutated NSCLC in a phase 1b trial.

The IMpactMF trial is being discontinued after an IDMC advised that imetelstat was unlikely to improve OS in relapsed/refractory myelofibrosis.
Advertisement
Advertisement
Trending on OncLive
1
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
2
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
3
Petosemtamab Plus Pembrolizumab Hits Phase 3 OS, ORR Primary End Points in PD-L1+ R/M HNSCC
4
Sac-TMT Plus Pembrolizumab Improves PFS in PD-L1–Negative Nonsquamous NSCLC
5







